Actively Recruiting
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Led by Boryung Pharmaceutical Co., Ltd · Updated on 2024-10-18
10000
Participants Needed
2
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
CONDITIONS
Official Title
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with type 2 diabetes who are scheduled to start a fixed-dose combination of dapagliflozin and pioglitazone at baseline (visit 1)
- Patients who voluntarily signed a written personal information collection and usage agreement after being informed about the study's objectives and methods
You will not qualify if you...
- Patients who have previously taken a fixed-dose combination of dapagliflozin and pioglitazone at baseline (visit 1)
- Patients expected to require insulin prescription during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Andong Hospital
Andong, Gyeongsangbuk-do, South Korea, 36743
Actively Recruiting
2
Konkuk University medical center
Seoul, South Korea
Not Yet Recruiting
Research Team
S
Shin-young Oh
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here